When a Philadelphia jury awarded three plaintiffs’ hormone replacement therapy cases against Pfizer last week at a combined total of $72.6 million in compensatory damages, plaintiffs attorneys said the verdict was all the more significant because it was rendered after the first phase of a reverse-bifurcated trial.

The parties confirmed that those cases settled for undisclosed amounts on the eve of the second phase of trial, which was originally scheduled to open Dec. 9.